Skip Nav Destination
Issues
15 March 2009
-
Cover Image
Cover Image
Alternatively activated M2 macrophages in xenograft model of CNS lymphoma. Fluorescently labeled antibodies were used to show the presence of intratumoral M2 macrophages using anti-CD11b (Alexa Fluor 594, red) and anti-Ym1 (Alexa Fluor 488, green) antibodies. The merged image indicates M2 macrophages exhibiting cytoplasmic expression of Ym-1. For further details, please see Kadoch and coworkers on page 1989 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
CCR Practice of Translational Oncology
Molecular Pathways
CCR Special Focus
Review
Human Cancer Biology
Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors
Eric M. Jackson; Angela J. Sievert; Xiaowu Gai; Hakon Hakonarson; Alexander R. Judkins; Laura Tooke; Juan Carlos Perin; Hongbo Xie; Tamim H. Shaikh; Jaclyn A. Biegel
Cancer Therapy: Preclinical
Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells
Giovanni Almanzar; Purevdorj B. Olkhanud; Monica Bodogai; Chiara Dell'Agnola; Dolgor Baatar; Stephen M. Hewitt; Claudio Ghimenton; Mohan K. Tummala; Ashani T. Weeraratna; Keith Sean Hoek; Natalay Kouprina; Vladimir Larionov; Arya Biragyn
Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model
Cigall Kadoch; Eduard B. Dinca; Ramona Voicu; Lingjing Chen; Diana Nguyen; Seema Parikh; Juliana Karrim; Marc A. Shuman; Clifford A. Lowell; Patrick A. Treseler; C. David James; James L. Rubenstein
Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
Agatha Labrinidis; Peter Diamond; Sally Martin; Shelley Hay; Vasilios Liapis; Irene Zinonos; Natalie A. Sims; Gerald J. Atkins; Cristina Vincent; Vladimir Ponomarev; David M. Findlay; Andrew C.W. Zannettino; Andreas Evdokiou
Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab
Alessandra Magnifico; Luisa Albano; Stefano Campaner; Domenico Delia; Fabio Castiglioni; Patrizia Gasparini; Gabriella Sozzi; Enrico Fontanella; Sylvie Menard; Elda Tagliabue
Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
Evelien W. Duiker; Elisabeth G.E. de Vries; Devalingam Mahalingam; Gert Jan Meersma; Wytske Boersma-van Ek; Harry Hollema; Marjolijn N. Lub-de Hooge; Go M. van Dam; Robbert H. Cool; Wim J. Quax; Afshin Samali; Ate G.J. van der Zee; Steven de Jong
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy
Yeon Hee Park; Sang Kyun Sohn; Jong Gwang Kim; Myung-Hoon Lee; Hong Suk Song; Min Kyoung Kim; Joo Seop Jung; Je-Joong Lee; Hyeoung Joon Kim; Dong Hwan Kim
p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli; Robert S. Warren; Donna Niedzwiecki; Elke Mueller; Carolyn C. Compton; Mark Redston; Margaret Hall; Hejin P. Hahn; Scott D. Jewell; Robert J. Mayer; Richard M. Goldberg; Leonard B. Saltz; Massimo Loda
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Ian D. Davis; Ben Brady; Richard F. Kefford; Michael Millward; Jonathan Cebon; Birte K. Skrumsager; Ulrik Mouritzen; Lasse Tengbjerg Hansen; Kresten Skak; Dorthe Lundsgaard; Klaus Stensgaard Frederiksen; Paul E.G. Kristjansen; Grant McArthur
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko; Arnold H. Zea; Brian I. Rini; Joanna L. Ireland; Paul Elson; Peter Cohen; Ali Golshayan; Patricia A. Rayman; Laura Wood; Jorge Garcia; Robert Dreicer; Ronald Bukowski; James H. Finke
A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer
Robert Mutter; Bo Lu; David P. Carbone; Ildiko Csiki; Luigi Moretti; David H. Johnson; Jason D. Morrow; Alan B. Sandler; Yu Shyr; Fei Ye; Hak Choy
Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Theo Nicholaou; Lisa M. Ebert; Ian D. Davis; Grant A. McArthur; Heather Jackson; Nektaria Dimopoulos; Bee Tan; Eugene Maraskovsky; Lena Miloradovic; Wendie Hopkins; Linda Pan; Ralph Venhaus; Eric W. Hoffman; Weisan Chen; Jonathan Cebon
Susceptibility and Prevention
Associations between Single Nucleotide Polymorphisms in Double-Stranded DNA Repair Pathway Genes and Familial Breast Cancer
Mary E. Sehl; Lucy R. Langer; Jeanette C. Papp; Lorna Kwan; Joyce L. Seldon; Geovanni Arellano; Jean Reiss; Elaine F. Reed; Sugandha Dandekar; Yael Korin; Janet S. Sinsheimer; Zuo-Feng Zhang; Patricia A. Ganz
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds